随着财报陆续出炉,2024年跨国药企的产品表现也揭晓,全球共有12款药品收入突破100亿美元。 中国企业距离登上这份榜单或许还需要一些时日,但在本土创新药产业快速崛起下,中国已经是全球第二大创新药国家。根据美国投行Stifel的数据,2024年大型制药公司的授权交易中有1/3来自中国,两年前这个数字为12%。这一势头有望在今年持续。 随着越来越多创新药出海,中国何时会出现收入破百亿美元的重磅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.